Vertex Pharmaceuticals, Orna Therapeutics announce research collaboration
Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Nasdaq13d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
Reuters28d
Vertex Pharmaceuticals Inc
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and progressive genetic disease, the company said on Friday, expanding its dominance ...
Benzinga.com1mon
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals VRTX, offering a diverse range of perspectives from bullish to bearish. The following table encapsulates ...